Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Genome-Based Bioinformatic Prediction of Major Histocompatibility (MHC).

Foote SJ.

Methods Mol Biol. 2019;2024:287-300. doi: 10.1007/978-1-4939-9597-4_18.

PMID:
31364057
2.

Recurrent miscalling of missense variation from short-read genome sequence data.

Field MA, Burgio G, Chuah A, Al Shekaili J, Hassan B, Al Sukaiti N, Foote SJ, Cook MC, Andrews TD.

BMC Genomics. 2019 Jul 16;20(Suppl 8):546. doi: 10.1186/s12864-019-5863-2.

3.

KCC1 Activation protects Mice from the Development of Experimental Cerebral Malaria.

Hortle E, Starrs L, Brown F, Jane S, Curtis D, McMorran BJ, Foote SJ, Burgio G.

Sci Rep. 2019 Apr 23;9(1):6356. doi: 10.1038/s41598-019-42782-x.

4.

Profiling of the Transcriptomic Responses of Clonostachys rosea Upon Treatment With Fusarium graminearum Secretome.

Demissie ZA, Foote SJ, Tan Y, Loewen MC.

Front Microbiol. 2018 Jun 7;9:1061. doi: 10.3389/fmicb.2018.01061. eCollection 2018.

5.

Bone marrow transplantation corrects haemolytic anaemia in a novel ENU mutagenesis mouse model of TPI deficiency.

Conway AJ, Brown FC, Hortle EJ, Burgio G, Foote SJ, Morton CJ, Jane SM, Curtis DJ.

Dis Model Mech. 2018 May 21;11(5). pii: dmm034678. doi: 10.1242/dmm.034678.

6.

Host genetics in malaria: lessons from mouse studies.

Huang HM, McMorran BJ, Foote SJ, Burgio G.

Mamm Genome. 2018 Aug;29(7-8):507-522. doi: 10.1007/s00335-018-9744-9. Epub 2018 Mar 28. Review.

PMID:
29594458
7.

Erythrocyte β spectrin can be genetically targeted to protect mice from malaria.

Lelliott PM, Huang HM, Dixon MW, Namvar A, Blanch AJ, Rajagopal V, Tilley L, Coban C, McMorran BJ, Foote SJ, Burgio G.

Blood Adv. 2017 Dec 12;1(26):2624-2636. doi: 10.1182/bloodadvances.2017009274. eCollection 2017 Dec 12.

8.

Effects of a Sprint Interval and Resistance Concurrent Exercise Training Program on Aerobic Capacity of Inactive Adult Women.

Salom Huffman L, Wadsworth DD, McDonald JR, Foote SJ, Hyatt H, Pascoe DD.

J Strength Cond Res. 2019 Jun;33(6):1640-1647. doi: 10.1519/JSC.0000000000002013.

PMID:
28777244
9.

Ankyrin-1 Gene Exhibits Allelic Heterogeneity in Conferring Protection Against Malaria.

Huang HM, Bauer DC, Lelliott PM, Dixon MWA, Tilley L, McMorran BJ, Foote SJ, Burgio G.

G3 (Bethesda). 2017 Sep 7;7(9):3133-3144. doi: 10.1534/g3.117.300079.

10.

Physical Activity, Sedentary Behavior, Fruit and Vegetable Consumption and Access: What Influences Obesity in Rural Children?

Daly CM, Foote SJ, Wadsworth DD.

J Community Health. 2017 Oct;42(5):968-973. doi: 10.1007/s10900-017-0343-6.

PMID:
28382455
11.

Griseofulvin impairs intraerythrocytic growth of Plasmodium falciparum through ferrochelatase inhibition but lacks activity in an experimental human infection study.

Smith CM, Jerkovic A, Truong TT, Foote SJ, McCarthy JS, McMorran BJ.

Sci Rep. 2017 Feb 8;7:41975. doi: 10.1038/srep41975.

12.

A novel ENU-induced ankyrin-1 mutation impairs parasite invasion and increases erythrocyte clearance during malaria infection in mice.

Huang HM, Bauer DC, Lelliott PM, Greth A, McMorran BJ, Foote SJ, Burgio G.

Sci Rep. 2016 Nov 16;6:37197. doi: 10.1038/srep37197.

13.

Adenosine monophosphate deaminase 3 activation shortens erythrocyte half-life and provides malaria resistance in mice.

Hortle E, Nijagal B, Bauer DC, Jensen LM, Ahn SB, Cockburn IA, Lampkin S, Tull D, McConville MJ, McMorran BJ, Foote SJ, Burgio G.

Blood. 2016 Sep 1;128(9):1290-301. doi: 10.1182/blood-2015-09-666834. Epub 2016 Jul 27.

14.

Genome-wide analysis of chemically induced mutations in mouse in phenotype-driven screens.

Bauer DC, McMorran BJ, Foote SJ, Burgio G.

BMC Genomics. 2015 Oct 26;16:866. doi: 10.1186/s12864-015-2073-4.

15.

Erythrocytic Iron Deficiency Enhances Susceptibility to Plasmodium chabaudi Infection in Mice Carrying a Missense Mutation in Transferrin Receptor 1.

Lelliott PM, McMorran BJ, Foote SJ, Burgio G.

Infect Immun. 2015 Nov;83(11):4322-34. doi: 10.1128/IAI.00926-15. Epub 2015 Aug 24.

16.

The influence of host genetics on erythrocytes and malaria infection: is there therapeutic potential?

Lelliott PM, McMorran BJ, Foote SJ, Burgio G.

Malar J. 2015 Jul 29;14:289. doi: 10.1186/s12936-015-0809-x. Review.

17.

In vivo assessment of rodent Plasmodium parasitemia and merozoite invasion by flow cytometry.

Lelliott PM, McMorran BJ, Foote SJ, Burgio G.

J Vis Exp. 2015 Apr 5;(98):e52736. doi: 10.3791/52736.

18.

Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites.

Smith CM, Jerkovic A, Puy H, Winship I, Deybach JC, Gouya L, van Dooren G, Goodman CD, Sturm A, Manceau H, McFadden GI, David P, Mercereau-Puijalon O, Burgio G, McMorran BJ, Foote SJ.

Blood. 2015 Jan 15;125(3):534-41. doi: 10.1182/blood-2014-04-567149. Epub 2014 Nov 20.

19.

A retrospective examination of mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study.

Blackburn NB, Charlesworth JC, Marthick JR, Tegg EM, Marsden KA, Srikanth V, Blangero J, Lowenthal RM, Foote SJ, Dickinson JL.

Oncol Rep. 2015 Jan;33(1):25-32. doi: 10.3892/or.2014.3568. Epub 2014 Oct 24.

20.

Treatment of erythrocytes with the 2-cys peroxiredoxin inhibitor, Conoidin A, prevents the growth of Plasmodium falciparum and enhances parasite sensitivity to chloroquine.

Brizuela M, Huang HM, Smith C, Burgio G, Foote SJ, McMorran BJ.

PLoS One. 2014 Apr 3;9(4):e92411. doi: 10.1371/journal.pone.0092411. eCollection 2014.

21.

A flow cytometric assay to quantify invasion of red blood cells by rodent Plasmodium parasites in vivo.

Lelliott PM, Lampkin S, McMorran BJ, Foote SJ, Burgio G.

Malar J. 2014 Mar 17;13:100. doi: 10.1186/1475-2875-13-100.

22.

Genome-based bioinformatic prediction of Major Histocompatibility Complex (MHC) epitopes.

Foote SJ.

Methods Mol Biol. 2013;1061:309-22. doi: 10.1007/978-1-62703-589-7_19.

PMID:
23963946
23.

Review of phosphocholine substituents on bacterial pathogen glycans: synthesis, structures and interactions with host proteins.

Young NM, Foote SJ, Wakarchuk WW.

Mol Immunol. 2013 Dec;56(4):563-73. doi: 10.1016/j.molimm.2013.05.237. Epub 2013 Aug 1. Review.

24.

New insights into the protective power of platelets in malaria infection.

McMorran BJ, Burgio G, Foote SJ.

Commun Integr Biol. 2013 May 1;6(3):e23653. doi: 10.4161/cib.23653.

25.

Bacterial growth at -15 °C; molecular insights from the permafrost bacterium Planococcus halocryophilus Or1.

Mykytczuk NC, Foote SJ, Omelon CR, Southam G, Greer CW, Whyte LG.

ISME J. 2013 Jun;7(6):1211-26. doi: 10.1038/ismej.2013.8. Epub 2013 Feb 7.

26.

Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum.

McMorran BJ, Wieczorski L, Drysdale KE, Chan JA, Huang HM, Smith C, Mitiku C, Beeson JG, Burgio G, Foote SJ.

Science. 2012 Dec 7;338(6112):1348-51. doi: 10.1126/science.1228892.

27.

Disulfide linkage engineering for improving biophysical properties of human VH domains.

Kim DY, Kandalaft H, Ding W, Ryan S, van Faassen H, Hirama T, Foote SJ, MacKenzie R, Tanha J.

Protein Eng Des Sel. 2012 Oct;25(10):581-9. Epub 2012 Aug 30.

PMID:
22942392
28.

A novel ENU-mutation in ankyrin-1 disrupts malaria parasite maturation in red blood cells of mice.

Greth A, Lampkin S, Mayura-Guru P, Rodda F, Drysdale K, Roberts-Thomson M, McMorran BJ, Foote SJ, Burgio G.

PLoS One. 2012;7(6):e38999. doi: 10.1371/journal.pone.0038999. Epub 2012 Jun 19.

29.

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.

Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI.

Ann Neurol. 2011 Dec;70(6):897-912. doi: 10.1002/ana.22609. Erratum in: Ann Neurol. 2013 Apr;73(4):561.

30.

Proteomic insights into cold adaptation of psychrotrophic and mesophilic Acidithiobacillus ferrooxidans strains.

Mykytczuk NC, Trevors JT, Foote SJ, Leduc LG, Ferroni GD, Twine SM.

Antonie Van Leeuwenhoek. 2011 Aug;100(2):259-77. doi: 10.1007/s10482-011-9584-z. Epub 2011 May 21.

PMID:
21604047
31.

Stargazin and AMPA receptor membrane expression is increased in the somatosensory cortex of Genetic Absence Epilepsy Rats from Strasbourg.

Kennard JT, Barmanray R, Sampurno S, Ozturk E, Reid CA, Paradiso L, D'Abaco GM, Kaye AH, Foote SJ, O'Brien TJ, Powell KL.

Neurobiol Dis. 2011 Apr;42(1):48-54. doi: 10.1016/j.nbd.2011.01.003. Epub 2011 Jan 8.

PMID:
21220022
32.

Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition.

Van der Walt A, Stankovich J, Bahlo M, Taylor BV, Van der Mei IA, Foote SJ, Rubio JP, Kilpatrick TJ, Butzkueven H.

Mult Scler. 2011 Mar;17(3):344-52. doi: 10.1177/1352458510389101. Epub 2010 Dec 13.

PMID:
21149397
33.

Anticipation in familial hematologic malignancies.

Tegg EM, Thomson RJ, Stankovich JM, Banks A, Marsden KA, Lowenthal RM, Foote SJ, Dickinson JL.

Blood. 2011 Jan 27;117(4):1308-10. doi: 10.1182/blood-2010-07-296475. Epub 2010 Nov 29.

34.

A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis.

Field J, Browning SR, Johnson LJ, Danoy P, Varney MD, Tait BD, Gandhi KS, Charlesworth JC, Heard RN; Australia and New Zealand Multiple Sclerosis Genetics Consortium, Stewart GJ, Kilpatrick TJ, Foote SJ, Bahlo M, Butzkueven H, Wiley J, Booth DR, Taylor BV, Brown MA, Rubio JP, Stankovich J.

PLoS One. 2010 Oct 26;5(10):e13454. doi: 10.1371/journal.pone.0013454.

35.

Evidence for a common genetic aetiology in high-risk families with multiple haematological malignancy subtypes.

Tegg EM, Thomson RJ, Stankovich J, Banks A, Flowers C, McWhirter R, Panton J, Piaszczyk A, Bahlo M, Marsden KA, Lowenthal RM, Foote SJ, Dickinson JL.

Br J Haematol. 2010 Aug;150(4):456-62. doi: 10.1111/j.1365-2141.2010.08267.x. Epub 2010 Jun 15.

PMID:
20560968
36.

Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.

Jensen CJ, Stankovich J, Van der Walt A, Bahlo M, Taylor BV, van der Mei IA, Foote SJ, Kilpatrick TJ, Johnson LJ, Wilkins E, Field J, Danoy P, Brown MA; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Rubio JP, Butzkueven H.

PLoS One. 2010 Apr 2;5(4):e10003. doi: 10.1371/journal.pone.0010003.

37.

Fine mapping of Leishmania major susceptibility Locus lmr2 and evidence of a role for Fli1 in disease and wound healing.

Sakthianandeswaren A, Curtis JM, Elso C, Kumar B, Baldwin TM, Lopaticki S, Kedzierski L, Smyth GK, Foote SJ, Handman E.

Infect Immun. 2010 Jun;78(6):2734-44. doi: 10.1128/IAI.00126-10. Epub 2010 Apr 5.

38.

Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy.

van der Walt A, Stankovich J, Bahlo M, Taylor BV, van der Mei IA, Foote SJ, Kilpatrick TJ, Rubio JP, Butzkueven H.

Neurology. 2009 Sep 29;73(13):1018-25. doi: 10.1212/WNL.0b013e3181b9c85e.

PMID:
19786693
39.

The role of host genetics in leishmaniasis.

Sakthianandeswaren A, Foote SJ, Handman E.

Trends Parasitol. 2009 Aug;25(8):383-91. doi: 10.1016/j.pt.2009.05.004. Epub 2009 Jul 18. Review.

PMID:
19617002
40.

HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis.

Stankovich J, Butzkueven H, Marriott M, Chapman C, Tubridy N, Tait BD, Varney MD, Taylor BV, Foote SJ; ANZgene Consortium, Kilpatrick TJ, Rubio JP.

Tissue Antigens. 2009 Jul;74(1):17-21. doi: 10.1111/j.1399-0039.2009.01262.x. Epub 2009 Apr 21.

PMID:
19392788
41.

Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus.

Perera D, Stankovich J, Butzkueven H, Taylor BV, Foote SJ, Kilpatrick TJ, Rubio JP.

J Neuroimmunol. 2009 Jun 25;211(1-2):105-9. doi: 10.1016/j.jneuroim.2009.03.010. Epub 2009 Apr 17.

PMID:
19375175
42.

Microarray-based comparative genomic profiling of reference strains and selected Canadian field isolates of Actinobacillus pleuropneumoniae.

Gouré J, Findlay WA, Deslandes V, Bouevitch A, Foote SJ, MacInnes JI, Coulton JW, Nash JH, Jacques M.

BMC Genomics. 2009 Feb 24;10:88. doi: 10.1186/1471-2164-10-88.

43.

Platelets kill intraerythrocytic malarial parasites and mediate survival to infection.

McMorran BJ, Marshall VM, de Graaf C, Drysdale KE, Shabbar M, Smyth GK, Corbin JE, Alexander WS, Foote SJ.

Science. 2009 Feb 6;323(5915):797-800. doi: 10.1126/science.1166296.

44.

Novel roles for erythroid Ankyrin-1 revealed through an ENU-induced null mouse mutant.

Rank G, Sutton R, Marshall V, Lundie RJ, Caddy J, Romeo T, Fernandez K, McCormack MP, Cooke BM, Foote SJ, Crabb BS, Curtis DJ, Hilton DJ, Kile BT, Jane SM.

Blood. 2009 Apr 2;113(14):3352-62. doi: 10.1182/blood-2008-08-172841. Epub 2009 Jan 28.

45.

A Cav3.2 T-type calcium channel point mutation has splice-variant-specific effects on function and segregates with seizure expression in a polygenic rat model of absence epilepsy.

Powell KL, Cain SM, Ng C, Sirdesai S, David LS, Kyi M, Garcia E, Tyson JR, Reid CA, Bahlo M, Foote SJ, Snutch TP, O'Brien TJ.

J Neurosci. 2009 Jan 14;29(2):371-80. doi: 10.1523/JNEUROSCI.5295-08.2009.

46.

Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians.

Rubio JP, Stankovich J, Field J, Tubridy N, Marriott M, Chapman C, Bahlo M, Perera D, Johnson LJ, Tait BD, Varney MD, Speed TP, Taylor BV, Foote SJ, Butzkueven H, Kilpatrick TJ.

Genes Immun. 2008 Oct;9(7):624-30. doi: 10.1038/gene.2008.59. Epub 2008 Jul 24.

PMID:
18650830
47.

Genetic absence epilepsy rats from Strasbourg have increased corticothalamic expression of stargazin.

Powell KL, Kyi M, Reid CA, Paradiso L, D'Abaco GM, Kaye AH, Foote SJ, O'Brien TJ.

Neurobiol Dis. 2008 Aug;31(2):261-5. doi: 10.1016/j.nbd.2008.04.012. Epub 2008 May 10.

PMID:
18556211
48.

Decreases in HCN mRNA expression in the hippocampus after kindling and status epilepticus in adult rats.

Powell KL, Ng C, O'Brien TJ, Xu SH, Williams DA, Foote SJ, Reid CA.

Epilepsia. 2008 Oct;49(10):1686-95. doi: 10.1111/j.1528-1167.2008.01593.x. Epub 2008 Apr 7.

49.

The complete genome sequence of Actinobacillus pleuropneumoniae L20 (serotype 5b).

Foote SJ, Bossé JT, Bouevitch AB, Langford PR, Young NM, Nash JH.

J Bacteriol. 2008 Feb;190(4):1495-6. Epub 2007 Dec 7.

50.

SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians.

Burfoot RK, Jensen CJ, Field J, Stankovich J, Varney MD, Johnson LJ, Butzkueven H, Booth D, Bahlo M, Tait BD, Taylor BV, Speed TP, Heard R, Stewart GJ, Foote SJ, Kilpatrick TJ, Rubio JP.

Tissue Antigens. 2008 Jan;71(1):42-50. Epub 2007 Oct 30.

PMID:
17971048

Supplemental Content

Loading ...
Support Center